Agreement - May 27, 2022
Orion enters into exclusive agreement with Jemincare
Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commercialization rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective NaV 1.8 blocker for the treatment of acute and chronic pain. Orion will also receive ownership to […]
Pharma Business - May 4, 2022
FDA accepts Orion’s sNDA and grants Priority Review
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The application is being conducted under the FDA Oncology […]
In a new job - April 20, 2022
Liisa Hurme appointed President & CEO of Orion Corporation as of November 2022
Orion Corporation’s Board of Directors has appointed Liisa Hurme as President and CEO of Orion Corporation and the Chair of the Executive Management Board of the Orion Group as of 1 November 2022, until which her predecessor Timo Lappalainen will hold the position. “We began an international recruitment process for a new CEO immediately after […]
Clinical Trials - February 21, 2022
Orion present results from the CYPIDES trial
Clinical phase I data on Orion’s ODM-208 were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). “ODM-208 is a first-in-class CYP11A1-inhibitor and we are excited that this novel approach works in some of the patients who have only a few effective treatment options available. The first results of CYPIDES are […]
Agreement - August 4, 2021
Orion signs agreement with Marinus Pharmaceuticals
Orion Corporation has signed a European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone, a GABAA receptor modulator being investigated in multiple rare seizure disorders. Under the terms of the agreement, Orion will have the right to sell and market ganaxolone in Europe. Orion has made an upfront payment of EUR 25 million to Marinus as a signing fee. Marinus is also […]
Collaboration - June 22, 2021
Orion to co-develop CAR T-cell cancer therapy
Orion Corporation and the Finnish Red Cross Blood Service have concluded an agreement on research collaboration with the aim of developing chimeric antigen receptor (CAR) T-cell therapy. The Blood Service has experience in cell research, in the supply of cord blood and stem cell grafts classified as tissue products, and in the preparation of ATMP […]
